Small Fiber Neuropathy

Small fiber neuropathy (SFN) is a disorder of the thinly myelinated A-delta and unmyelinated C fibers that mediate pain, temperature sensation, and autonomic function. Because routine nerve conduction studies (NCS) and electromyography (EMG) evaluate only large myelinated fibers, patients with SFN characteristically have normal electrodiagnostic testing — a finding that historically led to under-recognition and diagnostic delays. The clinical hallmark is burning, often length-dependent pain with preserved strength and reflexes, frequently accompanied by autonomic symptoms ranging from sudomotor dysfunction to orthostatic intolerance. Skin punch biopsy with intraepidermal nerve fiber density (IENFD) quantification has emerged as the gold standard diagnostic test, transforming the ability to objectively confirm small fiber involvement. Etiologies span from diabetes and prediabetes (the most common) to autoimmune conditions, sodium channelopathies, amyloidosis, and idiopathic causes, which account for up to half of cases.

Epidemiology

Population-based studies from Olmsted County, Minnesota, identified a minimum incidence of 1.3 per 100,000/year and prevalence of 13.3 per 100,000, with both figures increasing over the study period. A larger Dutch registry found substantially higher estimates — incidence of 12 per 100,000/year and prevalence of 53 per 100,000 — reflecting differences in diagnostic thresholds and ascertainment methods. These are considered minimum estimates, as SFN remains widely under-diagnosed. The condition is more common in patients over 65 years of age. Female sex, obesity, diabetes, insomnia, and hypertriglyceridemia are overrepresented among SFN cohorts. Importantly, most patients with isolated SFN do not develop major large-fiber neurologic impairments over time, though they carry an increased burden of comorbid conditions including cardiovascular disease.

Pathophysiology

Small fibers include the thinly myelinated A-delta fibers, which mediate sharp pain and cold temperature sensation, and unmyelinated C fibers, which convey burning pain, warmth sensation, and postganglionic autonomic signals. These fibers have their cell bodies in the dorsal root ganglia (somatic) and autonomic ganglia (autonomic), with terminal axons projecting into the epidermis as free nerve endings and to target organs including sweat glands, blood vessels, and viscera.

The pathogenic mechanisms vary by etiology. In diabetes and prediabetes, metabolic injury from hyperglycemia, oxidative stress, and advanced glycation end-products preferentially damages the metabolically vulnerable small fiber terminals. In autoimmune SFN, antibody-mediated or inflammatory mechanisms target the nerve fibers or dorsal root ganglia. In sodium channelopathies, gain-of-function mutations in voltage-gated sodium channels (NaV1.7, NaV1.8, NaV1.9) cause neuronal hyperexcitability and subsequent degeneration of small fibers. Regardless of the initiating mechanism, the final common pathway is loss of intraepidermal nerve fibers, measurable on skin biopsy.

Etiology

Clinical Features

Sensory Symptoms

The hallmark of SFN is neuropathic pain, most commonly described as burning, stinging, or "pins and needles." Pain typically begins in the feet and is often worse at night or with rest. Positive sensory symptoms predominate:

• Burning pain: The most characteristic symptom; often constant with superimposed paroxysms of lancinating or shocklike pain
• Allodynia: Pain from normally non-painful stimuli such as bedsheets or socks touching the feet
• Hyperalgesia: Exaggerated pain response to mildly painful stimuli
• Dysesthesia: Unpleasant abnormal sensations such as tingling, crawling, or itching

Negative sensory symptoms include reduced pinprick and temperature sensation in a length-dependent distribution. Importantly, vibration sense, proprioception, and light touch are preserved — these are large fiber modalities. Strength and deep tendon reflexes are normal on examination.

Autonomic Symptoms

Autonomic involvement is present in a significant proportion of SFN patients and may be the presenting feature in some cases. The spectrum includes:

• Sudomotor dysfunction: Decreased sweating (anhidrosis) in the feet with compensatory hyperhidrosis in proximal regions; heat intolerance
• Cardiovascular autonomic dysfunction: Orthostatic intolerance, postural tachycardia, and in severe cases, orthostatic hypotension
• Gastrointestinal dysmotility: Early satiety, nausea, constipation, diarrhea, or gastroparesis
• Urogenital dysfunction: Erectile dysfunction, bladder urgency or retention
• Sicca symptoms: Dry eyes and dry mouth (even in the absence of Sjögren syndrome)
• Vasomotor changes: Skin discoloration, Raynaud-like symptoms, or swelling in the distal extremities

Diagnosis

Skin Punch Biopsy (Gold Standard)

Skin punch biopsy with quantification of IENFD is the most validated and widely accepted diagnostic test for SFN. The technique was standardized by the European Federation of Neurological Societies/Peripheral Nerve Society (EFNS/PNS) joint task force guidelines.

• Technique: A 3 mm punch biopsy is taken from the distal leg, 10 cm above the lateral malleolus. A proximal site (thigh, 20 cm below the anterior iliac spine) may be biopsied to assess proximal-to-distal gradient
• Staining: PGP9.5 (protein gene product 9.5) immunohistochemistry to visualize intraepidermal nerve fibers crossing the dermal–epidermal junction
• Interpretation: IENFD below the 5th percentile for age- and sex-matched normative values is diagnostic. IENFD normally declines with age — age-specific reference ranges are essential
• Sensitivity: Approximately 70%–90% for SFN, depending on the clinical population and normative data used
• Advantages: Objective, quantitative, minimally invasive (performed under local anesthesia), and reproducible across laboratories following standardized protocols
• Limitations: May be normal in early or patchy SFN; normative values vary between laboratories; does not assess autonomic fiber function

Quantitative Sensory Testing (QST)

QST measures psychophysical thresholds for thermal (warm and cold detection, heat pain) and vibratory stimuli. Elevated warm detection and heat pain thresholds suggest A-delta and C fiber dysfunction. QST is useful as a supportive tool but has limitations: it is subjective (dependent on patient attention and cooperation), cannot distinguish peripheral from central pathology, and has high variability. QST alone is insufficient for diagnosis but strengthens diagnostic certainty when combined with clinical findings and skin biopsy.

Autonomic Function Testing

• Quantitative sudomotor axon reflex test (QSART): Measures postganglionic sympathetic cholinergic sudomotor function by stimulating sweat glands with acetylcholine iontophoresis. Abnormal in >70% of SFN patients. Reduced sweat volume indicates small fiber autonomic dysfunction
• Sudoscan: An electrochemical skin conductance test that evaluates sweat gland function. Non-invasive, rapid, and reproducible; emerging as a convenient screening tool though less well-validated than QSART
• Cardiovagal and adrenergic testing: Heart rate variability to deep breathing, Valsalva ratio, and tilt table testing assess cardiovascular autonomic function and can document orthostatic intolerance
• Thermoregulatory sweat test (TST): Topographical assessment of sweating patterns using indicator powder in a heated chamber; useful for detecting regional sudomotor deficits but limited availability

Corneal Confocal Microscopy (CCM)

CCM is a non-invasive, in-vivo imaging technique that quantifies corneal nerve fiber density, branch density, and fiber length in the sub-basal nerve plexus. The cornea is the most densely innervated tissue in the body, and its small fibers degenerate in SFN. CCM correlates with IENFD and can detect nerve fiber regeneration after treatment. Although promising as a rapid, repeatable diagnostic tool, CCM is not yet widely available outside specialized centers and lacks fully standardized normative databases.

Diagnostic Criteria

Laboratory Workup

Sodium Channelopathies in SFN

A major advance in understanding SFN pathogenesis has been the identification of gain-of-function mutations in voltage-gated sodium channel genes. These channels are predominantly expressed in dorsal root ganglion neurons and nociceptors, and mutations that enhance channel activity cause neuronal hyperexcitability, ectopic firing, and ultimately degeneration of small fibers.

• SCN9A (NaV1.7): The most frequently affected gene, found in approximately 10%–30% of SFN patients in some cohorts. NaV1.7 mutations cause the channel to remain partially open ("impaired inactivation"), leading to persistent sodium currents. These mutations are also linked to inherited erythromelalgia and paroxysmal extreme pain disorder
• SCN10A (NaV1.8): Accounts for approximately 5% of SFN cases. Mutations shift the voltage dependence of activation, causing the channel to open more readily. NaV1.8 mutations may also cause gastroparesis and other autonomic symptoms
• SCN11A (NaV1.9): A less commonly affected gene; gain-of-function mutations cause persistent sodium currents and dorsal root ganglion hyperexcitability

Sodium channelopathy-associated SFN typically presents at a younger age, often without traditional metabolic or autoimmune risk factors. A family history of neuropathic pain, erythromelalgia, or burning feet syndrome should prompt genetic testing. Overall, gain-of-function variants in sodium channel genes have been identified in approximately 12%–18% of patients with pure SFN.

Treatment

Treat the Underlying Cause

Identification and management of the underlying etiology is the cornerstone of SFN treatment and the only approach that may halt or reverse nerve fiber loss:

• Diabetes/prediabetes: Glycemic control, metabolic syndrome management, weight loss, and exercise. Exercise has been associated with improvement in symptoms and increased intraepidermal nerve fiber branching. Among type 2 diabetics, targeting metabolic syndrome components beyond glucose control alone is essential
• Autoimmune: Immunotherapy directed at the underlying disease (hydroxychloroquine for Sjögren, gluten-free diet for celiac, corticosteroids or steroid-sparing agents for sarcoidosis)
• Fabry disease: Enzyme replacement therapy (agalsidase alfa or beta) or oral chaperone therapy (migalastat)
• hATTR amyloidosis: Tafamidis (TTR stabilizer), patisiran or vutrisiran (RNA interference), or inotersen (antisense oligonucleotide)
• B12 deficiency: Supplementation with cyanocobalamin or methylcobalamin

Neuropathic Pain Management

Symptomatic pain management follows the same principles as for painful diabetic polyneuropathy, guided by the 2022 AAN practice guidelines. Monotherapy should be optimized before adding a second agent; combination therapy improves pain control in refractory cases.

Immunotherapy for Autoimmune and Idiopathic SFN

Intravenous immunoglobulin (IVIg) has been investigated for SFN, particularly in cases with suspected autoimmune pathogenesis:

• Uncontrolled studies and case series have reported improvements in pain scores and nerve fiber density with IVIg, especially in patients with identified autoimmune etiologies (Sjögren, sarcoidosis) or autoimmune markers
• However, the largest randomized controlled trial (60 patients with painful idiopathic SFN) found no significant difference between IVIg and placebo for pain reduction, IENFD improvement, or autonomic symptom scores
• A subset of patients with non-length-dependent SFN or positive Plexin D1 antibodies may respond, suggesting that patient selection is critical
• Current evidence does not support routine IVIg use for idiopathic SFN, but a trial may be considered in cases with strong autoimmune features and refractory symptoms

Sodium Channel Blockers for Channelopathies

Patients with genetically confirmed sodium channelopathy may benefit from targeted sodium channel blockade. Lacosamide, which selectively enhances slow inactivation of sodium channels, has shown promise in case reports and small series for SCN9A-associated SFN. Carbamazepine and oxcarbazepine are also used. Emerging selective NaV1.7 inhibitors are in clinical development and represent a potential precision medicine approach for this subgroup.

Autonomic Symptom Management

• Orthostatic intolerance: Increased fluid and salt intake, compression stockings, fludrocortisone, midodrine, or droxidopa for orthostatic hypotension
• Sudomotor dysfunction: Avoidance of heat exposure; topical glycopyrrolate for compensatory hyperhidrosis
• GI dysmotility: Small frequent meals, prokinetic agents (metoclopramide, domperidone) for gastroparesis; dietary modification for constipation
• Sicca symptoms: Artificial tears, saliva substitutes

Prognosis

The natural history of SFN varies by etiology. Diabetic and idiopathic SFN tend to follow a slowly progressive or stable course, with most patients not developing significant large fiber involvement or motor disability. Functional impairment is primarily driven by chronic pain and autonomic symptoms rather than weakness or sensory ataxia. Quality of life is often substantially reduced due to pain, sleep disruption, and autonomic dysfunction. In cases with a treatable underlying cause — particularly autoimmune conditions, Fabry disease, and hATTR amyloidosis — early intervention may stabilize or improve nerve fiber density. Sodium channelopathy-associated SFN follows a chronic course; targeted channel blockade may improve symptoms but does not reverse the underlying genetic defect. Population-based studies have shown that SFN patients carry increased cardiovascular comorbidity and all-cause mortality, underscoring the importance of comprehensive risk factor management.

References

1. Lauria G, Hsieh ST, Johansson O, et al. European Federation of Neurological Societies/Peripheral Nerve Society Guideline on the use of skin biopsy in the diagnosis of small fiber neuropathy. Eur J Neurol 2010;17(7):903–912.
2. Devigili G, Tugnoli V, Penza P, et al. The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 2008;131(Pt 7):1912–1925.
3. Terkelsen AJ, Karlsson P, Lauria G, et al. The diagnostic challenge of small fibre neuropathy: clinical presentations, evaluations, and causes. Lancet Neurol 2017;16(11):934–944.
4. Peters MJH, Bakkers M, Merkies ISJ, et al. Incidence and prevalence of small-fiber neuropathy: a survey in the Netherlands. Neurology 2013;81(15):1356–1360.
5. Kosmidis ML, Koutsogeorgopoulou L, Alexopoulos H, et al. Reduction of intraepidermal nerve fiber density (IENFD) in the skin biopsies of patients with fibromyalgia: a controlled study. J Neurol Sci 2014;347(1–2):143–147.
6. Faber CG, Hoeijmakers JGJ, Ahn HS, et al. Gain of function NaV1.7 mutations in idiopathic small fiber neuropathy. Ann Neurol 2012;71(1):26–39.
7. Faber CG, Lauria G, Merkies ISJ, et al. Gain-of-function NaV1.8 mutations in painful neuropathy. Proc Natl Acad Sci U S A 2012;109(47):19444–19449.
8. Huang J, Han C, Estacion M, et al. Gain-of-function mutations in sodium channel NaV1.9 in painful neuropathy. Brain 2014;137(Pt 6):1627–1642.
9. Hoeijmakers JGJ, Faber CG, Lauria G, Merkies ISJ, Waxman SG. Small-fibre neuropathies — advances in diagnosis, pathophysiology and management. Nat Rev Neurol 2012;8(7):369–379.
10. Themistocleous AC, Ramirez JD, Serra J, Bennett DLH. The clinical approach to small fibre neuropathy and painful channelopathy. Pract Neurol 2014;14(6):368–379.
11. Bakkers M, Faber CG, Hoeijmakers JGJ, Lauria G, Merkies ISJ. Small fibers, large impact: quality of life in small-fiber neuropathy. Muscle Nerve 2014;49(3):329–336.
12. Price R, Smith D, Franklin G, et al. Oral and topical treatment of painful diabetic polyneuropathy: practice guideline update summary. Neurology 2022;98(1):31–43.
13. Tesfaye S, Sloan G, Petrie J, et al. Comparison of amitriptyline supplemented with pregabalin, pregabalin supplemented with amitriptyline, and duloxetine supplemented with pregabalin for the treatment of diabetic peripheral neuropathic pain (OPTION-DM). Lancet 2022;400(10353):680–690.
14. Geerts M, de Greef BTA, Sopacua M, et al. Intravenous immunoglobulin therapy in patients with painful idiopathic small fiber neuropathy. Neurology 2021;96(20):e2534–e2545.
15. Liu X, Treister R, Lang M, Bhatt DL, Oaklander AL. IVIg for apparently autoimmune small-fiber polyneuropathy: first analysis of efficacy and safety. Ther Adv Neurol Disord 2018;11:1756285617744484.
16. de Greef BTA, Hoeijmakers JGJ, Gorber N, et al. Small fiber neuropathy incidence, prevalence, longitudinal impairments, and disability. Neurology 2022;98(4):e395–e405.
17. Tavee JO, Karwa K, Ahmed Z, Thompson N, Parambil J, Culver DA. Sarcoidosis-associated small fiber neuropathy in a large cohort: clinical aspects and response to IVIg and anti-TNF alpha treatment. Respir Med 2017;126:135–138.
18. Lauria G, Merkies ISJ, Faber CG. Small fibre neuropathy. Curr Opin Neurol 2012;25(5):542–549.
19. Sopacua M, Hoeijmakers JGJ, Merkies ISJ, Lauria G, Waxman SG, Faber CG. Small-fiber neuropathy: expanding the clinical pain universe. J Peripher Nerv Syst 2019;24(1):19–33.
20. Tavakoli M, Quattrini C, Abbott C, et al. Corneal confocal microscopy: a novel noninvasive test to diagnose and stratify the severity of human diabetic neuropathy. Diabetes Care 2010;33(8):1792–1797.
21. Callaghan BC, Price RS, Feldman EL. Distal symmetric polyneuropathy: a review. JAMA 2015;314(20):2172–2181.
22. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015;138(Pt 1):43–52.
23. Oaklander AL, Herzog ZD, Downs HM, Klein MM. Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia. Pain 2013;154(11):2310–2316.